X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
BPT-143, full-length, folded and PEGylated protein demonstrated power of protein synthesis platform to engineer pleiotropic native cytokines into optimized therapeutics and exploiting technology to develop pipeline of novel designer cytokines and multi-modal immune therapies.
Lead Product(s): BPT-143
Therapeutic Area: Oncology Product Name: BPT-143
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2022
Details:
Under the terms of the license agreement, Bright Peak will receive the right to develop, manufacture and commercialize PD-1 ICs, including LZM009 on a worldwide basis while Livzon retains certain rights of first negotiation to obtain exclusivity in the greater China territory.
Lead Product(s): LZM009
Therapeutic Area: Oncology Product Name: LZM009
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Livzon Pharmaceutical Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 16, 2021
Details:
BPT-143 is an enhanced, half-life extended, IL-2 cytokine that uses small modifications to amino acid side chains to block binding to IL-2 receptor alpha, and enhance binding to IL-2 receptor beta.
Lead Product(s): BPT-143
Therapeutic Area: Oncology Product Name: BPT-143
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: RA Capital
Deal Size: $107.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing June 10, 2021
Details:
As part of the collaboration and license agreement with Ajinomoto Co., the AJICAP® technology will be used to conjugate Bright Peak’s enhanced cytokines as payloads to certain antibodies, creating novel and proprietary Bright Peak Immunocytokines.
Lead Product(s): Immunocytokines
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Ajinomoto Bio-Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 25, 2021
Details:
Bright Peak’s technology platform allows a wide range of proteins to be chemically assembled de novo. The company has validated the platform by creating a portfolio of designer cytokines with the potential to be advanced as novel immune-oncology therapeutics.
Lead Product(s): IL-2 conjugates
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Ridgeline Therapeutics Discovery
Deal Size: $35.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing July 28, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
